Drugs / aBM-MNC
last change Jan 2022 re-read 2 minutes ago

aBM-MNC

Developed for
type 1 diabetes mellitus
Investigated by
Fuzhou General Hospital

Trials 1 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT01374854 Jan 2009 → Dec 2010 type 1 diabetes mellitus Fuzhou General Hospital Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as aBM-MNC “autologous bone marrow mononuclear cell (aBM-MNC) stem cell transplantation (SCT)” PMID 35086778 Jan 2022
Known as autologous bone marrow mononuclear cell autologous bone marrow mononuclear cell (aBM-MNC) stem cell transplantation (SCT)” PMID 35086778 Jan 2022
Known as Umbilical mesenchymal stem cell (UC-MSCs) infusion ClinicalTrials.gov intervention name — accepted as the source's own label NCT01374854
Route Other “106.8 × 10(6)/kg aBM-MNC through supraselective pancreatic artery cannulation” PMID 26628416 Dec 2015